PharmaShots

JULY 23, 2025

ADCs continue to possess the potential to provide a more impactful benefit to patients than chemotherapy alone, with a more limited toxicity profile. All patients in the study had progressed following platinum-based chemotherapy, and 90% of patients had progressed after immune checkpoint inhibitors. and 30% from China. mg/kg, 1.2

Chemotherapy 52

Chemotherapy Compounding Immunization Immunity 52

pharmaphorum

JULY 18, 2025

Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Chemotherapy 52

STAT

OCTOBER 25, 2023

The other scenario involved treatments that were more expensive, but no more effective than alternatives, such as the Abraxane chemotherapy. The researchers examined Medicare beneficiaries who were diagnosed with cancer and received treatment from 2014 through 2019.

Chemotherapy 362

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 362

STAT

OCTOBER 30, 2023

But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion. STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure.

Chemotherapy 342

Chemotherapy 342

STAT

OCTOBER 5, 2022

After the brain tumor diagnosis in 2016, Gatton would undergo two brain surgeries, radiation treatment, chemotherapy, followed by an embryo transfer that failed. But after all that, another embryo transfer had worked, and in fall 2019, Gatton was expecting. Read the rest…

Chemotherapy 260

Chemotherapy Hospitals 260

STAT

JULY 13, 2023

Although not new, drug shortages are now a crisis, with an increasing number of reports about cancer doctors having to ration chemotherapies and other drugs. At the request of a large bipartisan group of lawmakers, a task force chaired by the Food and Drug Administration in 2019 reported on the root causes of drug shortages.

Chemotherapy 246

Chemotherapy 246

pharmaphorum

DECEMBER 8, 2021

China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in a phase 3 trial as first-line therapy for extensive stage small cell lung cancer (ES-SCLC), setting up regulatory filings.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

MAY 10, 2022

The two companies have been working together since 2019 on digital health interventions to provide support to people with cancer, focusing initially on tools for patients undergoing cancer immunotherapy.

Chemotherapy 137

Chemotherapy Communication 137

Big Molecule Watch

MAY 22, 2023

According to the press release, FYLNETRA—Amneal’s third biosimilar launch in the United States since late last year—is used to treat neutropenia (low neutrophils, a type of white blood cell that fights infection) which is commonly experienced by patients undergoing chemotherapy.

Biosimilars 72

Biosimilars Chemotherapy 72

pharmaphorum

JULY 21, 2022

Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced disease, i.e. recurrent or relapsed HNSCC that has metastasised to other parts of the body.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

FEBRUARY 11, 2022

.” Hopes were high that a drug developed by Sangamo based on its zinc finger nuclease (ZFN) genome-editing technology could lead to the first therapy that could correct the genetic defect n MPS I, but that candidate – called SB-318 – flunked out in a clinical trial reported in 2019 and was discontinued.

Chemotherapy 111

Chemotherapy Drug Development 111

pharmaphorum

JUNE 8, 2021

Chemotherapy still accounted for 72.6% of the oncology market in China in 2019, compared to 17.1% million in 2019, and are estimated to increase to 5.7 Chemotherapy still plays a significant role in oncology treatment, accounting for 72.6% of the oncology market in China in 2019, compared to 17.1% million in 2030.

Chemotherapy 106

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunization 106

pharmaphorum

AUGUST 31, 2022

Kaiku’s DPPM platform has also attracted the attention of other big pharma groups, including Roche which has been working with the company since 2019 on personalised support modules for patients taking its PD-L1 inhibitor Tecentriq (atezolizumab).

Chemotherapy 116

Chemotherapy Immunization Immunity Hospitals 116

pharmaphorum

OCTOBER 19, 2020

MCL is generally treated first with chemotherapy, and patients whose disease progresses despite that can then receive stem cell transplantation or BTK inhibitor drugs like Johnson & Johnson/AbbVie’s Imbruvica (ibrutinib) and AstraZeneca’s Calquence (acalabrutinib).

Chemotherapy 124

Chemotherapy 124

Express Pharma

JULY 5, 2023

Venus Remedies has received marketing approvals from Oman, Malaysia, Bosnia and Trinidad and Tobago for key chemotherapy drugs. Pertinently, Malaysia, where the market size of cancer drugs was valued at $417 million in 2019, accounts for a sizeable revenue for Venus Remedies from the ASEAN region.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

AUGUST 4, 2021

The HDAC inhibitor was given an accelerated approval by the FDA as a second-line PTCL therapy on the strength of overall response data, but a phase 3 study comparing Istodax to first-line chemotherapy showed no improvement on progression-free survival (PFS).

Chemotherapy 98

Chemotherapy Labelling 98

pharmaphorum

MARCH 12, 2021

The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval for Retsevmo (selpercatinib) as monotherapy for adults with advance RET fusion-positive non-small cell lung cancer requiring systemic therapy after previous immunotherapy and/or chemotherapy treatment.

Chemotherapy 111

Chemotherapy Labelling 111

Pharmaceutical Commerce

JANUARY 19, 2024

Today's approval amends the accelerated approval granted by the FDA in April 2019 to Balversa (erdafitinib) for patients with metastatic urothelial carcinoma with susceptible FGFR2 or FGFR3 alterations following prior treatment with platinum-containing chemotherapy.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

SEPTEMBER 29, 2021

Alexion teamed up with Caelum on CAEL-101 in 2019, taking a minority stake in the company, and the partners advanced the drug into the phase 3 CARES programme last year. Each year, an estimated 4,500 people develop AL amyloidosis in the US alone, and there are an estimated 30,000 to 45,000 people living with the disease in the US and Europe.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

JUNE 6, 2022

Rozlytrek was approved by the FDA in 2019 but has just started to gather sales momentum, making around $17 million in the first quarter of this year, an increase of 78% on the first three months of 2021. Another research note from SVB Securities predicted that repotrectinib could eventually become a $1.5

Chemotherapy 98

Chemotherapy Labelling 98

pharmaphorum

APRIL 19, 2022

The review will mainly look at AZ and Daiichi Sankyo’s DESTINY-Lung01, a phase 2 trial which showed a 55% overall response rate for Enhertu in patients previously treated with platinum chemotherapy, mainly partial responses, with a median duration of response of just over 9 months. billion licensing deal for the drug in 2019.

Chemotherapy 105

Chemotherapy 105

pharmaphorum

FEBRUARY 15, 2021

To recap, Padcev (enfortumab vedotin) was quickly okayed by the FDA in December 2019 in advanced urothelial cancer on the basis of phase 2 response data that made it a rising star at that year’s American Society of Clinical Oncology (ASCO) conference. months in the chemotherapy group. of patients in the chemotherapy arm.

Chemotherapy 69

Chemotherapy 69

European Pharmaceutical Review

JULY 12, 2022

AstraZeneca’s blood-cancer treatment portfolio already includes Calquence (acalabrutinib), a chemotherapy-free monotherapy for patients with chronic lymphocytic leukaemia (CLL). . The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances.

Immunization 98

Immunization Immunity Chemotherapy 98

pharmaphorum

JANUARY 18, 2021

Until now people with AL amyloidosis have had to rely on chemotherapy, with its accompanying side effects, and other drugs to tackle organ failure once damage gets severe. Darzalex Faspro looks set to transform the prospects for the 30,000 to 45,000 people in the US and Europe AL amyloidosis patients.

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

MAY 17, 2023

Novel device opens blood-brain barrier to deliver chemotherapy Intratumoural delivery The current trial was designed to evaluate the combination of intratumoural DNX-2401 followed by intravenous pembrolizumab therapy. The study enrolled 49 patients with recurrent GBM from several institutions between September 2016 to January 2019.

Immunization 98

Immunization Immunity Chemotherapy 98

pharmaphorum

MARCH 30, 2022

The SKYSCRAPER-02 showed that the combination of the two drugs given on top of chemotherapy was unable to improve progression-free survival versus Tecentriq (atezolizumab) plus chemo in extensive-stage SCLC – a notoriously hard-to-treat form of lung cancer.

Chemotherapy 97

Chemotherapy Immunization Immunity 97

pharmaphorum

APRIL 27, 2021

Today (27 April), the ODAC is due to look at Tecentriq in combination with BMS/Celgene’s Abraxane (nab-paclitaxel) for people with advanced triple-negative breast cancer (TNBC) whose tumours express PD-L1, an indication which was provisionally approved by the FDA in 2019 on the strength of the Impassion130 study.

Chemotherapy 90

Chemotherapy Documentation Drug Development 90

pharmaphorum

JANUARY 20, 2021

Sobi acquired Doptelet via its $915 million takeover of Dova Pharmaceuticals in 2019, adding to its haematology and rare disease franchise. The European approval of Doptelet as a second-line treatment for ITP after therapies such as corticosteroids and immunoglobulin drugs comes after a green light by the FDA in July 2019.

Chemotherapy 52

Chemotherapy Immunization Immunity 52

Big Molecule Watch

MARCH 13, 2023

Udenyca (pegfilgrastim-cbqv) was first launched in the US in January 2019 and is one of six FDA approved pegfilgrastim biosimilars. Udenyca is administered the day after a chemotherapy treatment to decrease incidence of infection due to febrile neutropenia.

Biosimilars 52

Biosimilars Chemotherapy 52

pharmaphorum

AUGUST 11, 2021

. “This is welcome news for my patients, many of whom have already benefitted from the extra time this treatment gives them, without the need for chemotherapy,” said Dr Mark Verrill, a consultant medical oncologist at Newcastle upon Tyne Hospitals NHS Foundation Trust.

Chemotherapy 64

Chemotherapy Documentation Hospitals 64

pharmaphorum

DECEMBER 21, 2020

Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.

Biosimilars 126

Biosimilars Chemotherapy Immunization Immunity 126

Pharmaceutical Technology

MARCH 30, 2023

On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. This announcement is not the only recent development for Keytruda.

Chemotherapy 52

Chemotherapy Packaging Documentation 52

pharmaphorum

AUGUST 23, 2021

The latest disappointment has come from the phase 2 INTR@PID BTC 055 study of the drug alongside chemotherapy as a first-line treatment for patients with locally advanced or metastatic biliary tract cancer (BTC), which has been abandoned early. billion deal signed in 2019 that kicked off with a $363 million upfront payment.

Chemotherapy 52

Chemotherapy 52

European Pharmaceutical Review

OCTOBER 19, 2023

How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? There is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.

Chemotherapy 105

Chemotherapy Compounding Immunization Immunity 105

pharmaphorum

OCTOBER 1, 2021

GSK paid $360 million upfront in 2019 for a stake in bintrafusp alfa – a bifunctional fusion protein that targets PD-1 and TGF-beta – but Merck confirmed in a statement that it had no received any milestone payments from the alliance, which had been valued at up to $4.2 billion takeover of Tesaro in 2019.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

FEBRUARY 2, 2022

It’s the second acquisition in just a few weeks for Withings , which launched an electrocardiogram (ECG) enabled smartwatch in 2019 in a bid to take on market leader Apple, and also sells ‘smart’ scales and thermometers, blood pressure monitors, and sleep-tracking mattresses.

Chemotherapy 64

Chemotherapy Diabetes 64

pharmaphorum

MARCH 17, 2021

GSK snapped up rights to bintrafusp alfa in 2019, paying around $360 million upfront for a global stake in the drug – a bifunctional fusion protein that targets PD-1 and TGF-beta. The hypothesis that hitting both targets could boost the number of patients responding to PD-1 immunotherapy and the depth of that response is now looking shaky.

Chemotherapy 64

Chemotherapy 64